SecBot SecBot
8-K ·Filed Sep 16, 2026

ABOS

Acumen Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed1mo ago SEC0001628280-26-062137
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor upcoming filings or press releases for the actual disclosure content, as the 8-K indicates a Regulation FD item that may contain material information. Without document access, no immediate trading action is warranted.

DirectionNeutral
Confidencelow
Horizondays
Latest settled — T+20d
ABOS ▼ -30.46% at T+20d
NEUTRAL call -30.46% · α vs SPY -33.64% · entry $2.61 → $1.82
Next anchor: T+60d in 6w
Latest observation: T+27 -31.83% FF3 residual α
Entry = T+0 close
Sep 16, 2026
via day close
T+1d
-1.53%
call -1.53% · α -2.67%
$2.57
settled 6w ago
T+5d
-11.69%
call -11.69% · α -14.25%
$2.31
settled 5w ago
T+20d
-30.46%
call -30.46% · α -33.64%
$1.82
settled 13d ago
T+60d
Pending
in 6w

Price Chart

Loading chart...

Executive Summary

Acumen Pharmaceuticals filed an 8-K with Regulation FD disclosure (Item 7.01) and the accompanying exhibit (Item 9.01), but the document content was unavailable for analysis. The filing type suggests a routine public disclosure with no financial data or material events extractable from the provided information.

Key Facts

  • Filed Form 8-K with Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits)
  • Document content was unavailable; no quantitative data could be extracted

Financial Impact

No financial figures available in the provided documents.

Risk Factors

  • Inability to assess the nature or materiality of the disclosed information
  • Potential market reaction if the undisclosed content contains significant news

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-062137
Document: abos-20260916.htm0001628280-26-062137
Document: 0001628280-26-062137-index-headers.html0001628280-26-062137
Document: 0001628280-26-062137-index.html0001628280-26-062137
Document: 0001628280-26-062137.txt0001628280-26-062137
17 reports for ABOS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ABOS — sortable, filterable
TypeNow
Oct 26, 2026
today
S-3
BEARISH ★ 5/10
$2.27awaiting T+20—$2.27 (+0.01%)
Oct 26, 2026
today
8-K
NEUTRAL ★ 6/10
$2.07awaiting T+20—$2.27 (+9.71%)
Oct 26, 2026
today
Press Release
NEUTRAL ★ 5/10
$2.05awaiting T+20—$2.27 (+10.73%)
Oct 22, 2026
4d ago
Press Release
NEUTRAL ★ 3/10
$2.06awaiting T+20—$2.27 (+10.19%)
Oct 19, 2026
7d ago
Press Release
NEUTRAL ★ 1/10
$2.02awaiting T+20—$2.27 (+12.66%)
Sep 16, 2026
5w ago
8-K
NEUTRAL ★ 3/10
$2.61 $1.82▼ −30.46%▼ −33.64%$2.27 (−13.03%)
Aug 12, 2026
10w ago
Institutional Cluster
NEUTRAL ★ 4/10
$2.51 $2.86▲ +13.94%▲ +15.84%$2.27 (−9.56%)
Aug 12, 2026
10w ago
8-K
NEUTRAL ★ 5/10
$2.51 $2.86▲ +13.94%▲ +15.84%$2.27 (−9.56%)
Aug 12, 2026
10w ago
Press Release
BEARISH ★ 5/10
$2.51 $2.86▼ −13.94%▼ −15.84%$2.27 (+9.56%)
Jun 17, 2026
18w ago
Insider Cluster
NEUTRAL ★ 2/10
$2.26 $2.17▼ −3.98%▼ −4.52%$2.27 (+0.44%)
Showing 10 of 17

US Market Status

Market Closed — Opens in 8h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 16, 2026